A breakthrough trial testing a new University of Minnesota-developed drug resulted in improved survival rates for dogs diagnosed with a cancer called hemangiosarcoma (HSA). The results were published in the journal Molecular Cancer Therapeutics.
"This is likely the most significant advance in the treatment of canine HSA in the last three decades," said study co-author Jaime Modiano, a pro
All access premium subscription
This content requires a subscription to Feedstuffs in order to access. If you are a paid subscriber, use your email and password to Log In now.
Current Feedstuffs Subscribers: Online and mobile access are now included at no charge to you. To read this article, use your subscriber email and password to log-in to your account (or contact us for assistance in updating your account.)
Not Currently a Subscriber: Subscribe NOW to Feedstuffs and receive our print and/or digital publications, enewsletters and premium online content. Visit Feedstuffs.com and click on Subscribe at the top of the page for more information.
SUBSCRIBE NOW https://circulation.feedstuffs.com/Publications.aspx
TO RENEW YOUR SUBSCRIPTION https://circulation.feedstuffs.com/SubscriptionOffers.aspx